Skip to main content

Table 3 Baseline characteristics of the study population stratified by the incidence of sudden cardiac death (total population): Tehran Lipid and Glucose Study (1999–2018)

From: The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study

 

Without SCD

With SCD

P-value

Number of participants

4897

182

 

Continuous variables, Mean ± SD

 Age (year)

53.30 ± 9.77

62.62 ± 10.16

 < 0.01

 BMI (kg/m2)

27.89 ± 4.58

27.48 ± 5.04

0.24

 WC (cm)

92.63 ± 11.20

94.94 ± 11.87

 < 0.01

 WHR

0.91 ± 0.08

0.96 ± 0.08

 < 0.01

 SBP (mmHg)

125.70 ± 20.59

137.45 ± 25.58

 < 0.01

 DBP (mmHg)

80.00 ± 11.30

82.70 ± 14.29

 < 0.01

 RHR (beat/min)

78.35 ± 11.40

78.18 ± 12.80

0.85

 FPG (mg/dl)

104.36 ± 37.91

127.28 ± 64.10

 < 0.01

 HDL-C (mg/dl)

41.69 ± 10.94

41.18 ± 11.26

0.54

 TG (mg/dl)

165 (115–233)*

166 (118–235)*

0.90

Categorical variables, number (%)

 Men

2174 (44.39)

120 (65.93)

 < 0.01

 Current smoking, yes

761 (15.54)

42 (23.08)

 < 0.01

 Family History of premature CVD, yes

905 (18.48)

27 (14.84)

0.21

 Glucose-lowering drug use, yes

302 (6.17)

33 (18.13)

 < 0.01

 Antihypertensive drug use, yes

527 (10.76)

42 (23.08)

 < 0.01

 Lipid-lowering drug use, yes

239 (4.88)

13 (7.14)

0.17

  1. SD standard deviation, BMI body mass index, WC waist circumference, WHR waist to hip ratio, SBP systolic blood pressure, DBP diastolic blood pressure, RHR resting heart rate, FPG fasting plasma glucose, HDL-C high-density lipoprotein cholesterol, CVD cardiovascular disease
  2. *Data presented as median (IQR)